{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T20:05:04Z","timestamp":1776974704416,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40262-022-01148-9","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T18:03:57Z","timestamp":1656439437000},"page":"1393-1403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases"],"prefix":"10.1007","volume":"61","clinical-trial-number":[{"clinical-trial-number":"nct02081378","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03106779","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1406-8538","authenticated-orcid":false,"given":"Ying Fei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-7372","authenticated-orcid":false,"given":"Francois Pierre","family":"Combes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6405-9130","authenticated-orcid":false,"given":"Sherwin K. B.","family":"Sy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Yun","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,28]]},"reference":[{"issue":"6","key":"1148_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691\u2013709. https:\/\/doi.org\/10.1002\/ajh.25792.","journal-title":"Am J Hematol"},{"issue":"7","key":"1148_CR2","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","volume":"33","author":"M Houshmand","year":"2019","unstructured":"Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, et al. Chronic myeloid leukemia stem cells. Leukemia. 2019;33(7):1543\u201356. https:\/\/doi.org\/10.1038\/s41375-019-0490-0.","journal-title":"Leukemia"},{"issue":"1","key":"1148_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"J Cortes","year":"2021","unstructured":"Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14(1):44. https:\/\/doi.org\/10.1186\/s13045-021-01055-9.","journal-title":"J Hematol Oncol"},{"key":"1148_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98: 106458. https:\/\/doi.org\/10.1016\/j.leukres.2020.106458.","journal-title":"Leuk Res"},{"issue":"18","key":"1148_CR5","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61(18):8120\u201335. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01040.","journal-title":"J Med Chem"},{"issue":"8","key":"1148_CR6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/13543784.2021.1941863","volume":"30","author":"M Breccia","year":"2021","unstructured":"Breccia M, Colafigli G, Scalzulli E, Martelli M. Asciminib: an investigational agent for the treatment of chronic myeloid leukemia. Expert Opin Investig Drugs. 2021;30(8):803\u201311. https:\/\/doi.org\/10.1080\/13543784.2021.1941863.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7647","key":"1148_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543(7647):733\u20137. https:\/\/doi.org\/10.1038\/nature21702.","journal-title":"Nature"},{"issue":"2","key":"1148_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/00498254.2019.1594449","volume":"50","author":"P Tran","year":"2020","unstructured":"Tran P, Hanna I, Eggimann FK, Schoepfer J, Ray T, Zhu B, et al. Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects. Xenobiotica. 2020;50(2):160\u201370. https:\/\/doi.org\/10.1080\/00498254.2019.1594449.","journal-title":"Xenobiotica"},{"issue":"11","key":"1148_CR9","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/jcph.1926","volume":"61","author":"M Hoch","year":"2021","unstructured":"Hoch M, Sato M, Zack J, Quinlan M, Sengupta T, Allepuz A, et al. Pharmacokinetics of asciminib in individuals with hepatic or renal impairment. J Clin Pharm. 2021;61(11):1454\u201365. https:\/\/doi.org\/10.1002\/jcph.1926.","journal-title":"J Clin Pharm"},{"key":"1148_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13252","author":"M Hoch","year":"2022","unstructured":"Hoch M, Sengupta T, Hourcade-Potelleret F. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants. Clin Transl Sci. 2022. https:\/\/doi.org\/10.1111\/cts.13252 (Epub ahead of print).","journal-title":"Clin Transl Sci"},{"issue":"24","key":"1148_CR11","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. NEJM. 2019;381(24):2315\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1902328.","journal-title":"NEJM"},{"issue":"2","key":"1148_CR12","doi-asserted-by":"publisher","first-page":"LBA-4","DOI":"10.1182\/blood-2020-143816","volume":"136","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Boquimpani C, Rea D, Minami Y, Lomaia E, Voloshin S, et al. Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with \u22652 tyrosine kinase inhibitors (TKIs). Blood. 2020;136(2):LBA-4. https:\/\/doi.org\/10.1182\/blood-2020-143816.","journal-title":"Blood"},{"key":"1148_CR13","unstructured":"The Food and Drug Administration, USA. Highlights of asciminib prescribing information, in, October 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215358s000Orig1lbl.pdf. Accessed 11 Nov 2021."},{"issue":"7","key":"1148_CR14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","volume":"143","author":"J Geissler","year":"2017","unstructured":"Geissler J, Sharf G, Bombaci F, Daban M, De Jong J, Gavin T, et al. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol. 2017;143(7):1167\u201376. https:\/\/doi.org\/10.1007\/s00432-017-2372-z (Epub 2017 Mar 13 PMID: 28289895).","journal-title":"J Cancer Res Clin Oncol"},{"key":"1148_CR15","unstructured":"Combes F, Li YF, Sy S, Lorenzo S, Dasgupta K, Kapoor S, et al. Dose Justification for asciminib in patients with Ph+ chronic myeloid leukemia in chronic phase with or without the T315I mutation previously treated with two or more tyrosine kinase inhibitors. In: ePoster Presented at The American Association of Pharmaceutical Scientists (AAPS), October 17\u201320, 2021. Philadelphia, Pennsylvania. Hybrid event. Poster# T6107V"}],"updated-by":[{"DOI":"10.1007\/s40262-022-01166-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000}}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01148-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01148-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01148-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T02:37:05Z","timestamp":1665542225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01148-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,28]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1148"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01148-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40262-022-01166-7","asserted-by":"object"}]},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,28]]},"assertion":[{"value":"29 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40262-022-01166-7","URL":"https:\/\/doi.org\/10.1007\/s40262-022-01166-7","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees of Novartis. SL, SS, YFL, Y-YH, MH, and FPC own Novartis shares. FPC also owns Simulation Plus shares.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anonymized patient\u2010level data from clinical trials may be shared by Novartis in a consortium called ClinicalStudyDataRequest.com (CSDR) in accordance with Novartis\u2019 policy for sharing clinical trial data ().","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All the authors contributed to designing and performing the research, data analysis, and drafting and review of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}